KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Q3 2025 value amounting to $203000.0.

  • Jazz Pharmaceuticals' Exchange Rate Effect fell 9338.98% to $203000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 7615.48%. This contributed to the annual value of -$1.7 million for FY2024, which is 24731.75% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Exchange Rate Effect of $203000.0 as of Q3 2025, which was down 9338.98% from $4.6 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Exchange Rate Effect high stood at $4.9 million for Q4 2022, and its period low was -$5.4 million during Q3 2022.
  • In the last 5 years, Jazz Pharmaceuticals' Exchange Rate Effect had a median value of -$641000.0 in 2021 and averaged -$181315.8.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Exchange Rate Effect tumbled by 233235.29% in 2024, and later surged by 70922.27% in 2025.
  • Jazz Pharmaceuticals' Exchange Rate Effect (Quarter) stood at -$1.4 million in 2021, then soared by 456.06% to $4.9 million in 2022, then tumbled by 63.75% to $1.8 million in 2023, then plummeted by 227.95% to -$2.3 million in 2024, then skyrocketed by 108.87% to $203000.0 in 2025.
  • Its last three reported values are $203000.0 in Q3 2025, $4.6 million for Q2 2025, and $1.7 million during Q1 2025.